A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer

@inproceedings{Zhao2017ARP,
  title={A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer},
  author={Yannan Zhao and Chengcheng Gong and Zhonghua Wang and Jian Zhang and Leiping Wang and Sheng Zhang and Jun Cao and Zhonghua Tao and Ting Li and Bi Yun Wang and Xi-Chun Hu},
  booktitle={Oncotarget},
  year={2017}
}
Background Everolimus significantly improves progression-free survival (PFS) and has been approved to use in aromatase inhibitor pretreated patients with hormone receptor positive advanced breast cancer. Metformin has been shown to inhibit mTOR pathway, with more favorable safety profile, leading to this hypothesis-generating trial to assess whether… CONTINUE READING